Current Medical Care Situation of Patients in Germany Undergoing Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Ethical and Regulatory Framework
2.2. Technical Aspects of PIPAC Application
2.3. Histological Regression Analysis
3. Results
3.1. German PIPAC-Data
3.2. Single Center Data
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Goere, D.; Soudka, A.; Faron, M.; Faron, M.; Cloutier, A.S.; Viana, B.; Honoré, C.; Dumont, F.; Elias, D. Extent of colorectal peritoneal carcinomatosis: Attempt to define a threshold above which HIPEC does not offer survival benefit: A comparative study. Ann. Surg. Oncol. 2015, 22, 2958–2964. [Google Scholar] [CrossRef] [PubMed]
- Glehen, O.; Gilly, F.N.; Arvieux, C.; Cotte, E.; Boutitie, F.; Mansvelt, B.; Bereder, J.M.; Lorimier, G.; Quenet, F.; Elias, D. Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann. Surg. Oncol. 2010, 17, 2370–2377. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zanon, C.; Clara, R.; Chiappino, I.; Bortolini, M.; Cornaglia, S.; Simone, P.; Bruno, F.; De Riu, L.; Airoldi, M.; Pedani, F. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J. Surg. 2004, 28, 1040–1045. [Google Scholar] [CrossRef] [PubMed]
- Di Giorgio, A.; Naticchioni, E.; Biacchi, D.; Sibio, S.; Accarpio, F.; Rocco, M.; Tarquini, S.; Di Seri, M.; Ciardi, A.; Montruccoli, D.; et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008, 113, 315–325. [Google Scholar] [CrossRef] [PubMed]
- Cotte, E.; Glehen, O.; Mohamed, F.; Lamy, F.; Falandry, C.; Golfier, F.; Gilly, F.N. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: Prospective study of 81 patients. World J. Surg. 2007, 31, 1813–1820. [Google Scholar] [CrossRef] [PubMed]
- van Oudheusden, T.R.; Braam, H.J.; Nienhuijs, S.W.; Wiezer, M.J.; van Ramshorst, B.; Luyer, P.; de Hingh, I.H. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. J. Surg. Oncol. 2015, 111, 237–242. [Google Scholar] [CrossRef] [PubMed]
- Solomon, D.; DeNicola, N.; Feingold, D.; Liu, P.H.; Aycart, S.; Golas, B.J.; Sarpel, U.; Labow, D.M.; Magge, D.R. Signet ring cell features with peritoneal carcinomatosis in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with poor overall survival. J. Surg. Oncol. 2019, 119, 758–765. [Google Scholar] [CrossRef] [PubMed]
- Alyami, M.; Hübner, M.; Grass, F.; Bakrin, N.; Villeneuve, L.; Laplace, N.; Passot, G.; Glehen, O.; Kepenekian, V. Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications. Lancet Oncol. 2019, 20, e368–e377. [Google Scholar] [CrossRef]
- Available online: http://www.an-institut.de (accessed on 3 January 2018).
- He, Z.; Zhao, T.T.; Xu, H.M.; Wang, Z.N.; Xu, Y.Y.; Song, Y.X.; Ni, Z.R.; Xu, H.; Yin, S.C.; Liu, X.Y.; et al. Efficacy and safety of intraperitoneal chemotherapy in patients with advanced gastric cancer: A cumulative meta-analysis of randomized controlled trials. Oncotarget 2017, 8, 81125–8113611. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elit, L.; Oliver, T.K.; Covens, A.; Kwon, J.; Fung, M.F.; Hirte, H.W.; Oza, A.M. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: A systematic review with metaanalyses. Cancer 2007, 109, 692–702. [Google Scholar] [CrossRef] [PubMed]
- Levine, E.A.; Votanopoulos, K.I.; Shen, P.; Russell, G.; Fenstermaker, J.; Mansfield, P.; Bartlett, D.; Stewart, J.H. A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. J. Am. Coll. Surg. 2018, 226, 434–443. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van Driel, W.J.; Koole, S.N.; Sikorska, K.; Schagen van Leeuwen, J.H.; Schreuder, H.W.R.; Hermans, R.H.M.; de Hingh, I.H.J.T.; van der Velden, J.; Arts, H.J.; Massuger, L.F.A.G.; et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N. Engl. J. Med. 2018, 378, 230–240. [Google Scholar] [CrossRef] [PubMed]
- Provencher, D.M.; Gallagher, C.J.; Parulekar, W.R.; Ledermann, J.A.; Armstrong, D.K.; Brundage, M.; Gourley, C.; Romero, I.; Gonzalez-Martin, A.; Feeney, M.; et al. OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann. Oncol. 2018, 29, 431–438. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Armstrong, D.K.; Bundy, B.; Wenzel, L.; Huang, H.Q.; Baergen, R.; Lele, S.; Copeland, L.J.; Walker, J.L.; Burger, R.A.; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006, 354, 34–43. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walker, J.L.; Armstrong, D.K.; Huang, H.Q.; Fowler, J.; Webster, K.; Burger, R.A.; Clarke-Pearson, D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol. Oncol. 2006, 100, 27–32. [Google Scholar] [CrossRef] [PubMed]
- Bonvalot, S.; Cavalcanti, A.; Le Péchoux, C.; Terrier, P.; Vanel, D.; Blay, J.Y.; Le Cesne, A.; Elias, D. Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. Eur. J. Surg. Oncol. 2005, 31, 917–923. [Google Scholar] [CrossRef] [PubMed]
- Solass, W.; Kerb, R.; Mürdter, T.; Giger-Pabst, U.; Strumberg, D.; Tempfer, C.; Zieren, J.; Schwab, M.; Reymond, M.A. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy. Ann. Surg. Oncol. 2014, 21, 553–559. [Google Scholar] [CrossRef]
- Demtröder, C.; Solass, W.; Zieren, J.; Strumberg, D.; Giger-Pabst, U.; Reymond, M.A. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal. Dis. 2016, 18, 364–371. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nadiradze, G.; Giger-Pabst, U.; Zieren, J.; Strumberg, D.; Solass, W.; Reymond, M.A. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis. J. Gastrointest. Surg. 2016, 20, 367–373. [Google Scholar] [CrossRef] [Green Version]
- Sugarbaker, P.H. Management of peritoneal metastases-Basic concepts. J. BUON 2015, 2015, S2–S11. [Google Scholar]
- Göhler, D.; Khosrawipour, V.; Khosrawipour, T.; Diaz-Carballo, D.; Falkenstein, T.A.; Zieren, J.; Stintz, M.; Giger-Pabst, U. Technical description of the microinjection pump (MIP®) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg. Endosc. 2017, 31, 1778–1784. [Google Scholar] [CrossRef] [PubMed]
- Khosrawipour, V.; Khosrawipour, T.; Falkenstein, T.A.; Diaz-Carballo, D.; Förster, E.; Osma, A.; Adamietz, I.A.; Zieren, J.; Fakhrian, K. Evaluating the Effect of Micropump© Position, Internal Pressure and Doxorubicin Dosage on Efficacy of Pressurized Intra-peritoneal Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. Anticancer. Res. 2016, 36, 4595–4600. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Solass, W.; Giger-Pabst, U.; Zieren, J.; Reymond, M.A. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): Occupational health and safety aspects. Ann. Surg. Oncol. 2013, 20, 3504–3511. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harter, P.; Sehouli, J.; Vergote, I.; Ferron, G.; Reuss, A.; Meier, W.; Greggi, S.; Mosgard, B.J.; Selle, F.; Guyon, F.; et al. DESKTOP III Investigators. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N. Engl. J. Med. 2021, 385, 2123–2131. [Google Scholar] [CrossRef]
- Javanbakht, M.; Mashayekhi, A.; Branagan-Harris, M.; Horvath, P.; Königsrainer, A.; Reymond, M.A.; Yaghoubi, M. Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis. Eur. J. Surg. Oncol. 2021, 48, 188–196. [Google Scholar] [CrossRef] [PubMed]
- Graversen, M.; Detlefsen, S.; Bjerregaard, J.K.; Fristrup, C.W.; Pfeiffer, P.; Mortensen, M.B. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther. Adv. Med. Oncol. 2018, 10, 1758835918777036. [Google Scholar] [CrossRef] [PubMed]
- Tempfer, C.B.; Winnekendonk, G.; Solass, W.; Horvat, R.; Giger-Pabst, U.; Zieren, J.; Rezniczek, G.A.; Reymond, M.A. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. Gynecol. Oncol. 2015, 137, 223–228. [Google Scholar] [CrossRef] [PubMed]
- Graversen, M.; Detlefsen, S.; Pfeiffer, P.; Lundell, L.; Mortensen, M.B. Acute respiratory distress syndrome (ARDS) after pressurized intraperitoneal aerosol chemotherapy with oxaliplatin: A case report. Pleura Peritoneum. 2021, 6, 167–170. [Google Scholar]
- Graversen, M.; Detlefsen, S.; Pfeiffer, P.; Lundell, L.; Mortensen, M.B. Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): Report of two cases and literature survey. Clin. Exp. Metastasis. 2018, 35, 103–108. [Google Scholar] [CrossRef]
- Graversen, M.; Detlefsen, S.; Fristrup, C.; Pfeiffer, P.; Mortensen, M.B. Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high-risk colon cancer patients—Study protocol for the PIPAC-OPC3 Trial. A prospective, controlled phase 2 Study. Pleura Peritoneum. 2018, 3, 20180107. [Google Scholar] [CrossRef] [Green Version]
- Willaert, W.; Van de Sande, L.; Van Daele, E.; Van De Putte, D.; Van Nieuwenhove, Y.; Pattyn, P.; Ceelen, W. Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis. Eur. J. Surg. Oncol. 2019, 45, 2302–2309. [Google Scholar] [CrossRef] [PubMed]
- Robella, M.; De Simone, M.; Berchialla, P.; Argenziano, M.; Borsano, A.; Ansari, S.; Abollino, O.; Ficiarà, E.; Cinquegrana, A.; Cavalli, R.; et al. A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis. Cancers 2021, 13, 1060. [Google Scholar] [CrossRef] [PubMed]
- Tate, S.J.; Van de Sande, L.; Ceelen, W.P.; Torkington, J.; Parker, A.L. The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses. Pharmaceutics 2021, 13, 2043. [Google Scholar] [CrossRef] [PubMed]
Parameter | Cohort (n = 534) |
---|---|
Sex (male) % (n) | 41 (219) |
Tumor etiology % (n) | |
Colon Ovarian Gastric Mesothelioma Not defined (C78) | 1 (4) 1 (3) 4 (20) 6 (34) 88 (473) |
Complication rate % (n) | |
Total | 8 (36) |
Complication type % (n) | |
Bleedina anemia Pleural effusion Respiratory insufficiency Paralytic ileus Renal failure | 1 (5) 2 (10) 1 (5) 3 (13) 1 (3) |
In-hospital mortality | 0% |
Parameter | Cohort (n = 44) |
---|---|
Median Age (range) | 50 (27–77) |
Sex (male) % (n) | 50 (22) |
Tumor etiology % (n) | |
Gastric | 100 (44) |
Median PCI (range) | 27 (1–39) |
Disease setting % (n) | |
Synchronous Metachronous | 61 (27) 39 (17) |
HIPEC compound % (n) | |
Cisplatin/Doxorubicin Doxorubicin | 97 (43) 3 (1) |
Karnofsky-Index (%) median (range) | 80 (60–100) |
Non-access rate % (n) | 0 (0) |
>2 PIPAC applications % (n) | 57 (25) |
Adhesiolysis % (n) | 9 (4) |
Ascites (ml) median (range) | 80 (0–8000) |
PRGS median (range) | 2 (1–4) |
Histological regression % (n) | |
No regression Stable Regression | 32 (8) 44 (11) 24 (6) |
Operative time (min) median(range) | 101 (43–210) |
Survival (days) | 181 (43–636) |
In-hospital mortality | 0% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Horvath, P.; Yurttas, C.; Baur, I.; Steidle, C.; Reymond, M.A.; Girotti, P.N.C.; Königsrainer, A.; Königsrainer, I. Current Medical Care Situation of Patients in Germany Undergoing Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Cancers 2022, 14, 1443. https://doi.org/10.3390/cancers14061443
Horvath P, Yurttas C, Baur I, Steidle C, Reymond MA, Girotti PNC, Königsrainer A, Königsrainer I. Current Medical Care Situation of Patients in Germany Undergoing Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Cancers. 2022; 14(6):1443. https://doi.org/10.3390/cancers14061443
Chicago/Turabian StyleHorvath, Philipp, Can Yurttas, Isabella Baur, Christoph Steidle, Marc André Reymond, Paolo Nicola Camillo Girotti, Alfred Königsrainer, and Ingmar Königsrainer. 2022. "Current Medical Care Situation of Patients in Germany Undergoing Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)" Cancers 14, no. 6: 1443. https://doi.org/10.3390/cancers14061443